Jiangsu Huili Biotechnology Completes Series A Financing

Jiangsu Huili Biotechnology Co., Ltd. (Huili Bio), a Hong Kong-based next-generation synthetic biology enzyme computational design platform, completed its Series A financing round with hundreds of million RMB.

The round was co-led by Legend Capital.

The company intends to use the funds to accelerate the construction and operation of large-scale production facilities, the R&D of new product pipelines and the expansion of the talent team.

Founded in 2018, Huili Bio is dedicated to the computational design of enzyme components at the core of synthetic biological reactions via comprehensive capabilities in core technology, mass production on a large scale and closed-loop commercialization. It provides solutions in multiple fields such as pharmaceutical intermediates, animal protection and food. In addition to an R&D center in Tianjin, Huili Bio has also established a production base in Taizhou City, Jiangsu Province, which is under the expansion of flexible production line.